Prolacta Bioscience, a provider of specialty human milk formulas for premature and critically ill infants, said it raised $5 million in a Series B round for clinical studies.
Prolacta Bioscience, a provider of specialty human milk formulas for premature and critically ill infants, said it raised $5 million in a Series B round for clinical studies.
